Antineutrophil cytoplasmic antibody-associated active scleritis

Lani T. Hoang, Lyndell L. Lim, Brian Vaillant, Dongseok Choi, James (Jim) Rosenbaum

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Objective: To determine whether antineutrophil cytoplasmic antibody (ANCA) testing provides prognostic information in evaluating scleritis. Methods: Retrospective medical record review of patients evaluated at a tertiary care center from January 1, 1995, to June 30, 2006, was performed to compare clinical features, treatments, and associated systemic disease in patients who test positive for ANCA vs patients whose ANCA tests are negative. Results: Among 78 patients identified, 14 tested positive for ANCA. Patients with positive ANCA test results were more likely to have an associated systemic disorder (10 of 14 or 71%) than were patients who tested negative for ANCA (26 of 64 or 41%; P=.04), and the disorder was more likely to have been diagnosed as a result of scleritis work-up (2 of 10 or 20% vs 19 of 26 or 73%; P=.007). Patients with positive ANCA test results had significantly more ocular complications (21 of 14 or 86% vs 20 of 64 or 31%; P.001), including keratopathy (5 of 14 or 36% vs 6 of 64 or 9%; P=.02), visual acuity of 20/50 or worse (8 of 14 or 57% vs 11 of 64 or 17%; P=.001), and vascular pannus (3 of 14 or 21% vs 1 of 64 or 2%; P=.02). Aggressive therapy, such as chronic systemic corticosteroids (9 of 14 or 64% vs 9 of 64 or 14%; P <.001) and alkylator therapy (8 of 14 or 57% vs 7 of 64 or 11%; P <.001), was more likely to be recommended for patients who tested positive for ANCA. Conclusions: A substantial subset of patients with scleritis are also positive for ANCA. These patients are more likely to have severe ocular disease and undiagnosed primary vasculitic disease, thereby requiring more aggressive therapy. An ANCA test may be useful in the evaluation and treatment of patients with scleritis.

Original languageEnglish (US)
Pages (from-to)651-655
Number of pages5
JournalArchives of Ophthalmology
Volume126
Issue number5
DOIs
StatePublished - May 2008

Fingerprint

Scleritis
Antineutrophil Cytoplasmic Antibodies
Therapeutics
Eye Diseases
Alkylating Agents
Tertiary Care Centers
Visual Acuity
Medical Records
Blood Vessels
Adrenal Cortex Hormones

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Antineutrophil cytoplasmic antibody-associated active scleritis. / Hoang, Lani T.; Lim, Lyndell L.; Vaillant, Brian; Choi, Dongseok; Rosenbaum, James (Jim).

In: Archives of Ophthalmology, Vol. 126, No. 5, 05.2008, p. 651-655.

Research output: Contribution to journalArticle

Hoang, Lani T. ; Lim, Lyndell L. ; Vaillant, Brian ; Choi, Dongseok ; Rosenbaum, James (Jim). / Antineutrophil cytoplasmic antibody-associated active scleritis. In: Archives of Ophthalmology. 2008 ; Vol. 126, No. 5. pp. 651-655.
@article{445a4465f5fb4c6089d9151c1b1dcadc,
title = "Antineutrophil cytoplasmic antibody-associated active scleritis",
abstract = "Objective: To determine whether antineutrophil cytoplasmic antibody (ANCA) testing provides prognostic information in evaluating scleritis. Methods: Retrospective medical record review of patients evaluated at a tertiary care center from January 1, 1995, to June 30, 2006, was performed to compare clinical features, treatments, and associated systemic disease in patients who test positive for ANCA vs patients whose ANCA tests are negative. Results: Among 78 patients identified, 14 tested positive for ANCA. Patients with positive ANCA test results were more likely to have an associated systemic disorder (10 of 14 or 71{\%}) than were patients who tested negative for ANCA (26 of 64 or 41{\%}; P=.04), and the disorder was more likely to have been diagnosed as a result of scleritis work-up (2 of 10 or 20{\%} vs 19 of 26 or 73{\%}; P=.007). Patients with positive ANCA test results had significantly more ocular complications (21 of 14 or 86{\%} vs 20 of 64 or 31{\%}; P.001), including keratopathy (5 of 14 or 36{\%} vs 6 of 64 or 9{\%}; P=.02), visual acuity of 20/50 or worse (8 of 14 or 57{\%} vs 11 of 64 or 17{\%}; P=.001), and vascular pannus (3 of 14 or 21{\%} vs 1 of 64 or 2{\%}; P=.02). Aggressive therapy, such as chronic systemic corticosteroids (9 of 14 or 64{\%} vs 9 of 64 or 14{\%}; P <.001) and alkylator therapy (8 of 14 or 57{\%} vs 7 of 64 or 11{\%}; P <.001), was more likely to be recommended for patients who tested positive for ANCA. Conclusions: A substantial subset of patients with scleritis are also positive for ANCA. These patients are more likely to have severe ocular disease and undiagnosed primary vasculitic disease, thereby requiring more aggressive therapy. An ANCA test may be useful in the evaluation and treatment of patients with scleritis.",
author = "Hoang, {Lani T.} and Lim, {Lyndell L.} and Brian Vaillant and Dongseok Choi and Rosenbaum, {James (Jim)}",
year = "2008",
month = "5",
doi = "10.1001/archopht.126.5.651",
language = "English (US)",
volume = "126",
pages = "651--655",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "5",

}

TY - JOUR

T1 - Antineutrophil cytoplasmic antibody-associated active scleritis

AU - Hoang, Lani T.

AU - Lim, Lyndell L.

AU - Vaillant, Brian

AU - Choi, Dongseok

AU - Rosenbaum, James (Jim)

PY - 2008/5

Y1 - 2008/5

N2 - Objective: To determine whether antineutrophil cytoplasmic antibody (ANCA) testing provides prognostic information in evaluating scleritis. Methods: Retrospective medical record review of patients evaluated at a tertiary care center from January 1, 1995, to June 30, 2006, was performed to compare clinical features, treatments, and associated systemic disease in patients who test positive for ANCA vs patients whose ANCA tests are negative. Results: Among 78 patients identified, 14 tested positive for ANCA. Patients with positive ANCA test results were more likely to have an associated systemic disorder (10 of 14 or 71%) than were patients who tested negative for ANCA (26 of 64 or 41%; P=.04), and the disorder was more likely to have been diagnosed as a result of scleritis work-up (2 of 10 or 20% vs 19 of 26 or 73%; P=.007). Patients with positive ANCA test results had significantly more ocular complications (21 of 14 or 86% vs 20 of 64 or 31%; P.001), including keratopathy (5 of 14 or 36% vs 6 of 64 or 9%; P=.02), visual acuity of 20/50 or worse (8 of 14 or 57% vs 11 of 64 or 17%; P=.001), and vascular pannus (3 of 14 or 21% vs 1 of 64 or 2%; P=.02). Aggressive therapy, such as chronic systemic corticosteroids (9 of 14 or 64% vs 9 of 64 or 14%; P <.001) and alkylator therapy (8 of 14 or 57% vs 7 of 64 or 11%; P <.001), was more likely to be recommended for patients who tested positive for ANCA. Conclusions: A substantial subset of patients with scleritis are also positive for ANCA. These patients are more likely to have severe ocular disease and undiagnosed primary vasculitic disease, thereby requiring more aggressive therapy. An ANCA test may be useful in the evaluation and treatment of patients with scleritis.

AB - Objective: To determine whether antineutrophil cytoplasmic antibody (ANCA) testing provides prognostic information in evaluating scleritis. Methods: Retrospective medical record review of patients evaluated at a tertiary care center from January 1, 1995, to June 30, 2006, was performed to compare clinical features, treatments, and associated systemic disease in patients who test positive for ANCA vs patients whose ANCA tests are negative. Results: Among 78 patients identified, 14 tested positive for ANCA. Patients with positive ANCA test results were more likely to have an associated systemic disorder (10 of 14 or 71%) than were patients who tested negative for ANCA (26 of 64 or 41%; P=.04), and the disorder was more likely to have been diagnosed as a result of scleritis work-up (2 of 10 or 20% vs 19 of 26 or 73%; P=.007). Patients with positive ANCA test results had significantly more ocular complications (21 of 14 or 86% vs 20 of 64 or 31%; P.001), including keratopathy (5 of 14 or 36% vs 6 of 64 or 9%; P=.02), visual acuity of 20/50 or worse (8 of 14 or 57% vs 11 of 64 or 17%; P=.001), and vascular pannus (3 of 14 or 21% vs 1 of 64 or 2%; P=.02). Aggressive therapy, such as chronic systemic corticosteroids (9 of 14 or 64% vs 9 of 64 or 14%; P <.001) and alkylator therapy (8 of 14 or 57% vs 7 of 64 or 11%; P <.001), was more likely to be recommended for patients who tested positive for ANCA. Conclusions: A substantial subset of patients with scleritis are also positive for ANCA. These patients are more likely to have severe ocular disease and undiagnosed primary vasculitic disease, thereby requiring more aggressive therapy. An ANCA test may be useful in the evaluation and treatment of patients with scleritis.

UR - http://www.scopus.com/inward/record.url?scp=43549114083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43549114083&partnerID=8YFLogxK

U2 - 10.1001/archopht.126.5.651

DO - 10.1001/archopht.126.5.651

M3 - Article

C2 - 18474775

AN - SCOPUS:43549114083

VL - 126

SP - 651

EP - 655

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 5

ER -